IL-17A in LCH: Systemic biomarker, local factor, or none of the above?

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1405-1406

  Hogarty, Michael D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; MESSENGER RNA;

CYTOKINE RELEASE; DEGENERATIVE DISEASE; DENDRITIC CELL; DISEASE COURSE; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HISTIOCYTOSIS X; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORTALITY; NEOPLASM; NEVUS; NOTE; PRECANCER; PROTEIN FUNCTION; RARE DISEASE;

EID: 79961062175     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.150     Document Type: Note

References (4)

1. Coury, F, Annels, N, Rivollier, A, Olsson, S, Santoro, A, Speziani, C et al. (2008). Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14: 81-87.
2. Peters, TL, McClain, KL, Allen, CE (2011). Neither IL- 17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther 19: 1433-1439.
3. Badalian-Very, G, Vergilio, JA, Degar, BA, MacConaill, LE, Brandner, B, Calicchio, ML et al. (2010). Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116: 1919-1923.
4. Allen, CE, McClain, KL (2009). Interleukin-17A is not expressed by CD207+ cells in Langerhans cell histiocytosis lesions. Nat Med 15: 483-484; author reply 484.